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The construction of the 68Ge/68Ga generator has increased application of radiopharmaceuti-
cals  labeled with this isotope in medicine. 68Ga-PET is widely employed in the management
of  neuroendocrine tumors but favorable chemistry with tri- and tetraaza-ring molecules has
opened wide range of 68Ga application in other ﬁelds of PET imaging. This review covers the
radiopharmaceuticals labeled with gallium in molecular imaging and shows perspectives
on  the use of gallium-68 as a substitute for technetium-99, ﬂuorine-18 and carbon-11 ineywords:
osition emission tomography
8Ga labeled compounds
ifunctional chelators
8Gallium-DOTA-peptides
some applications.
© 2014 Greater Poland Cancer Centre. Published by Elsevier Urban & Partner Sp. z o.o. All
rights reserved..  Background
he positron emission tomography (PET) technique is applied
n the study of functioning and functional changes in the
uman body, enabling, among others, precise oncology diag-
ostics. It is as well an appreciated diagnostic method in
eurology and cardiology, allowing to evaluate the condition
f the respective systems in a non-invasive way.
The dominant isotope in these types of diagnostics is
uorine-18, widely used in the research and the clinical appli-
ations. The source of the isotope is a proton medical cyclotron
ith particle energies from 10 to 20 MeV  range which lim-
ts the availability of the isotope to the diagnostic centers,
here the operation of such a machine is economically justi-
ed and qualiﬁed personnel to operate and maintain such an
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507-1367/© 2014 Greater Poland Cancer Centre. Published by Elsevier Uequipment is available. Looking at the history of another iso-
tope, technetium-99m, widely used in the related ﬁeld of
nuclear medicine – scintigraphy, it can be seen that it is critical
to the development of the clinical applications to increase the
availability of the isotope.
Three isotopes of gallium can be used in nuclear medicine:
gallium-66, potentially useful as a PET tracer, gallium-67, for
the scintigraphy of the inﬂammation sites as citrate or with
labeled leukocytes, still considered as a routine tool for infec-
tion imaging and gallium-68, a fast growing PET radionuclide,
especially in cancer diagnostics.
In opposition to ﬂuorine-18 or carbon-11-based PET diag-
nostics, gallium-68 does not require the use of cyclotrons,
thereby reducing costs and increasing ﬂexibility in the practice
of nuclear medicine diagnostic imaging. In recent years,
gallium-68 has gained importance in molecular imaging by
rban & Partner Sp. z o.o. All rights reserved.
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Table 1 – Chemical properties of Fe, Ga, Tc and In.
Iron Gallium Technetium Indium
Atomic number 26 31 43 49
Ionic radius [pm] 64 62 136 80
Oxidation state III III I, III, IV, V, VII III
Coordination number 6 4, 5, 6 5, 6, 7 6, 7, 8
Complex geometry Octahedral Octahedral Octahedral,
trigonal
bipyramid,
square pyramidal
Octahedral,
square
antiprismatic
Radionuclide • 67Ga 68Ga 99mTc 111In
Diagnostic mode • SPECT 
Half-life • 3.56 d 
Source • Cyclotron 
positron emission tomography, due to the advantages of the
easy availability both from the 68Ge/68Ga generator and the
cyclotrons (natZn(p,n)68Ga) with 7–16 MeV  protons,1 good radi-
ation properties and rich Ga3+ coordination chemistry. The
quality of imaging is in some applications comparable to
the quality of imaging with ﬂuorine-18 isotope. In the near-
est future these factors may cause a serious increase in
the interest in gallium-68 labeled compounds in biology and
medicine.2–4
This review indicates the growing importance of the radio-
pharmaceuticals labeled with gallium in molecular imaging
and shows the perspectives on the use of gallium-68 as a sub-
stitute for technetium-99 in some applications.
2.  Gallium  chemistry
Gallium is a metal in group 13 of the periodic table. In aque-
ous acidic solutions, it occurs as a free, hydrated Ga3+ ion, in
slightly acidic and neutral pH hydrolyses to insoluble Ga(OH)3
but nanomolar concentrations, it is used for the formulation
of radiopharmaceuticals, can be obtained without precipita-
tion. In contrast to Tc(V), where improper reaction conditions
lead to insoluble and unreactive TcO2, amphoteric properties
of gallium allow the redissolution of the formed hydroxide.
If the concentration exceeds the nanomolar level, addition of
the carboxylic acids (citrate, oxalate, acetate) prevents precip-
itation. At higher pH, above 7, gallium hydroxide redissolves
as [Ga(OH)4]−.
Gallium is classiﬁed as hard Lewis acid and can form
octahedral complexes with hard Lewis bases, such as oxy-
gen and nitrogen atoms. Carboxylic, phosphonate, thiol and
amino groups form strong six-coordinate complexes, thermo-
dynamically and kinetically stable at physiological conditions.
Existing ﬁve and four-coordinate gallium complexes are more
sensitive to hydrolysis but are enough inert on the time-scale
of the gallium applications.
The coordination chemistry and biological properties of Ga
are similar to Fe ion (Table 1). Both are 3+ ions with compara-
ble ionic radius and dominating octahedral complex geometry,
thus the biomolecules with high Fe afﬁnity could be eas-
ily labeled with Ga–ligand exchange between intravenously
applied gallium citrate and transferrin, abundant plasma pro-
tein, forms a complex used for imaging of inﬂammatory sites.
Another element whose coordination chemistry is of great
interest for the development of gallium compounds, is indium.PET SPECT SPECT
1.13 h 6.02 h 2.83 d
Generator Generator Cyclotron
As a hard Lewis acid, In3+ prefers hard bases and forms sta-
ble complexes with nitrogen and oxygen atoms. Only higher
ionic radius (80 pm vs. 60 pm for Ga) differentiates the ligands
against a cavity size, where In ﬁts perfectly the tetraaza-
macrocyclic ligands (DOTA, Fig. 1a), while Ga prefers smaller
triaza rings (NOTA, Fig. 1b).
3.  Generators
Gallium-68 is a positron emitter with a half-life of 67.6 min
and dominantly decays via 1.92 MeV  positron emission (89%)
and electron capture (11%). The relatively short half-life and
hydrophilic nature are beneﬁcial for the rapid renal clearance
and reduce effective dose for the patient. Gallium-68 can be
conveniently and economically obtained from the 68Ge/68Ga
generator and the long half-life of the parent nuclide 68Ge
(t1/2 = 271 days) allows long-term PET imaging on-site. Thereby,
the introduction of gallium-68 generator has opened access
to the PET radioisotopes for diagnostic sites, located outside
production centers equipped with cyclotrons. The availabil-
ity of the 68Ge/68Ga generator system also provides imaging
centers with a PET nuclide that is routinely available in a man-
ner similar to the generator-produced single-photon emission
computed tomography nuclide technetium-99m, with added
value of better resolution and sensitivity. Thus, the devel-
opment of gallium radioisotopes and diagnostics procedures
combined with on-demand production and operation in the
absence of cyclotron facilities provides a reasonable devel-
opment pathway for gallium-68 labeled compounds in the
molecular imaging.
Although the ﬁrst gallium-68 generators have been used
already in the 60s, the chemical forms of the isotope as the
inert complexes, prevented the practical application and the
development of gallium radiochemistry. The second problem
was  the presence of signiﬁcant amounts of parent nuclide
and other metallic impurities in eluate. Both of these factors
resulted in the temporary loss of interest in applications of
gallium-68, but as a complex with EDTA has been used in
clinical practice that time and was the + source in the devel-
opment of the PET scanners. Practical applications of the ﬁrst
gallium generators have been described recently.5Beginning of the 21st century saw new developments in
the construction of generators. Various resins, using inorganic
oxides (TiO2, IGG100 68Ga generator; Eckert&ZieglerEurope),6
SnO27 and nanoparticles8 or organic polymers, containing
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Fig. 1 – Examples of the ligands DOTA (a), NOTA (b), and derivatives: NODAGA (c), OXO-DO3A (d), NODASA (e) and NODAPA (f).
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o-methylglucamine groups9 or lauryl gallate (ITG GmBH,
ermany) were constructed and successfully applied. Con-
emporary 68Ge/68Ga generator can be used for 1–2 years and
he gallium-68 build-up is rapid enough to allow multiple
adiotracer preparations daily.
The gallium-68 eluted from the inorganic generator often
uffered from the contamination by other metals, which
nﬂuenced negatively radiolabelling.10 Commonly observed
mpurities are: Fe(III), Al(III) and Zn(II) at the mg/L levels, Ni(II),
o(II), Cd(II) and Cu(II) at 0.01–0.1 mg/L and traces of Mn, Pb,
r, V.7,11 Average gallium-68 breakthrough varies from 10−4
o 10−5%. The most critical impurities are 68Ge, Fe(III), Zn(II),
n(II), thus additional puriﬁcation and removal of the metal
ontaminants has to be applied. The most popular proce-
ures differentiate gallium species (Ga3+ cations and anionic
GaCl4]−) depending on pH and chloride concentration and
hen separate on the respective ion exchangers. Typically,
8Ga3+ is trapped on the strong cation exchange cartridge
SCX), then converted with HCl, HCl/acetone or NaCl into
68GaCl4]− and transferred with a small volume of concen-
rated HCl to the strong anion exchange cartridge (SAX) and
nally eluted with water or slightly acidic solution.12–15 The
rocess could be easily automated for the reproducible prepa-
ation of ready-to-use 68Ga3+ in optimal activity and chemical
orm for labeling.16
The generators based on zirconium nanoparticles and
rganic matrix could be eluted under milder conditions and
allium-68 ions are easier to form suitable complexes for
linical use. Furthermore, they suffer less from the metallic
ontaminants and the puriﬁcation processes could be omitted
r simpliﬁed.17At the time of this publication, at least four types of the
generators with different construction and scalable activity
are available commercially and more  than 100 centers across
the world use this type of generator, both for the basic research
on gallium-68 radiochemistry and the clinical trials.18
4.  Radiopharmaceuticals
The rapid development of radiopharmaceuticals labeled with
gallium is due to the synergy between a growing importance
of the PET diagnostics in the molecular imaging and the use
of long-term experience with the technetium generators. The
trivalent cation 68Ga3+ is eluted from the generator and its
chemical form allows simple and universal application in
radiopharmaceutical preparations with an appropriate chela-
tor. Ga3+ ion has complexing properties comparable to those
of Fe(III) and In(III) but can easily adapt to various Tc targeting
concepts (Table 2), resulting in a large group of molecules (vec-
tors), with well-established and proved practical applications
in the molecular imaging.
4.1.  Gallium-68  bifunctional  chelators  (BFC)  in  the
neuroendocrine  tumor  imaging
The bifunctional chelators are compounds acting as a con-
jugate between the radioisotope and a vector. The BFC’s key
features are the ability to quickly and steadily incorporate
the isotope and create covalent bonds with biomolecules,
responsible for targeting. Over the past decade, the interest
in it is inseparably connected with the synthesis and use of
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Table 2 – 99mTc tracers with their 68Ga analogs.
Diagnostics 99mTc 68Ga
Peptide receptors 99mTc-HYNIC-peptide 68Ga-DOTA-peptide
Bone metastases 99mTc-MDP 68Ga-phosphonates
Renal function 99mTc-DTPA/MAG3/DMSA 68Ga-EDTA
Cardiac function 99mTc-RBC/MIBI 68Ga-BAPEN
Lung function 99mTc-MAA 68Ga-MAA
Hepatobiliary 99mTc-IDA 68Ga-IDA
Infection 99mTc-WBC 68Ga-citrate
Brain imaging (perfusion) 99mTc-ECD 68Ga-ECD
Abbreviations:  HYNIC, hydrazinonicotinamide; MDP, methylenediphosphonic acid; DTPA, diethylenetriaminepentaacetic acid; MAG3, mercap-
toacetyltriglycine; DMSA, dimercaptosuccinic acid; RBC, red blood cell; MIBI, methoxyisobutylisonitrile; MAA, macroaggregated albumin;
inate
aminIDA, iminodiacetic acid; WBC, white blood cell; ECD, ethyl cyste
dimethoxysalicylaldimine)-N,N′-bis(3-aminopropyl)-N,N′-ethylenedi
radiolabeled peptides for positron emission tomography (PET)
in the clinical and preclinical diagnostics, as well as with the
radiation-based therapeutics.
The macrocyclic chelators with three or four nitrogen
atoms in a ring have been established as frequently consid-
ered routes for the introduction of gallium-68. Between them,
the molecules with tri- and tetraaza-ring have become the
most prevalent since irreversible complexation of the gallium
atom, thermodynamic stability and superior kinetic even at
room temperature. External substituents, usually in the form
of carboxyl groups allow convenient conjugation to various
targeting molecules.
DOTA (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic
acid) remains the most frequently used chelator because of its
availability and well-recognized coordination chemistry.2 Its
six coordinate triaza-ring analog NOTA ((1,4,7-triazanonane-
1,4,7-triyl)triacetic acid) forms slightly deformed octahe-
dral complexes with gallium-68 which display higher
stabilities and faster incorporation of Ga(III) at lower
temperatures.18 A signiﬁcant number of compounds, sim-
ilar to DOTA and NOTA have been used for speciﬁc
applications (Fig. 2): bifunctional derivatives of NOTA –
NODAGA (1,4,7-triazacyclononane,1-glutaric acid-4,7-acetic
acid) and NODASA (1,4,7-triazacyclononane-1-succinic acid-
4,7-diacetic acid) are limited to coupling peptides through
an amide bond, NODAPA (1,4,7-triazacyclononane-1,4-diacetic
acid-7-p-phenyl-acetic acid) with hydroxyl group (NODAPA-
OH) or thiocyanate groups (NODAPA-(NCS)n) have been
successfully applied as versatile bifunctional chelators.19
Many  receptors are overexpressed in cancer cells, thus
the targeted peptides with aminoacids sequences speciﬁc for
activity centers, labeled with appropriate radioisotope via BFC,
have been used for the development of highly speciﬁc imaging
probes for PET and/or therapeutic agents.
68Ga-DOTA-peptides are a group of PET tracers that
speciﬁcally bind to somatostatin receptors (SST) that are
over-expressed on the neuroendocrine tumor (NET) cells.20
Targeting agents are coupled via the BFC leveraging standard
intermediates that enable covalent attachment of peptides,
including active octapeptides (octreotride, OC) and related
3 3 8peptide analogs, TOC (Tyr -OC), TATE (Tyr -Thr -OC) and NOC
(NaI3-OC) (Fig. 2). Six different SST receptors have been identi-
ﬁed (SST1, 2A, 2B, 3, 4, 5) in humans. Of the analogs mentioned
above, DOTA-TOC and DOTA-TATE show a high afﬁnity for the dimer; EDTA, ethylenediaminetetraacetic acid; BAPEN, Tris(4,6-
e.
SSTR2, although a 10-fold higher afﬁnity for the SSTR2 has
been demonstrated for DOTA-TATE as compared to DOTATOC
in vitro in the transfected cell cultures. Their binding afﬁnity
to SSTR5 is quite low and that to SSTR3 is almost negligible
and there is no considerable afﬁnity to SSTR1 and SSTR4. For
DOTA-NOC, high afﬁnities for SSTRs’ 2,3 and 5 were reported,21
which improves the binding proﬁle and extends the spectrum
of targeted tumors.
Despite the variations in somatostatine receptors afﬁnity,
all described compounds (68Ga-DOTA-TOC, -NOC, -TATE) have
been reported to be accurate for the localization of well  differ-
entiated NET lesions, performing better than CT.22
Comparing to other modalities, studies have shown the
superiority of PET over 111In-pentetreotide-SPECT in the detec-
tion of metastases and unknown primary neuroendocrine
tumors. PET imaging using 68Ga-SSTR has also been found
to be more  accurate than 18F-FDOPA-PET in non-carcinoid
tumors. [68Ga]-DOTA-TATE detected more  tumor sites than
[123I]-MIBG in patients with the neural crest tumors (includ-
ing paragangliomas). Only one bone lesion in one patient with
adrenal paraganglioma was detected on [123I]-MIBG scan but
not in [68Ga]-DOTA-TATE.23–29
Radionuclide-labeled DOTA-SSTR analogs are used for
diagnostics and therapy of the neuroendocrine tumors. Typ-
ically, 68Ga-DOTA-TOC is used for diagnosis, while the same
compound labeled with high- or medium-energy -emitters
such as yttrium-90 or lutetium-177 is used for therapy. The
use of coupled diagnostic and therapeutic isotopes with ligand
for treatment of NET allows better planning of therapy and to
evaluate the therapeutic outcome as in personalized medicine
where the diagnosis is tailored to the subsequent therapy. It
inﬂuenced radiopharmaceutical sciences with the “theranos-
tics” concept, which combines gallium-68 diagnostics with
trivalent therapeutic radiometals (yttrium-90, lutetium-177,
bismuth-213)30 with improved personal dosimetry.31
4.2.  Behind  the  NET  –  applications  of 68Ga-BFC-core
Two main trends could be observed in the development of
methods and applications of the gallium-68 radiopharmaceu-
ticals, other than NET-focused. First, using the technetium
“shake‘n’shoot” concept, has focused attention to the use of
gallium-68 as technetium-99m substitute in the part of appli-
cations. Recently published papers have presented efﬁcient
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Fig. 2 – Structures of DOTA-TOC (a), DOTA-NOC (b), and DOTA-TATE (c). The most clinically applied 68Ga-labeled
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allium-68 labeling of commercially available phosphonate
its for scintigraphy of bone lesions,32,33 MAA (macroag-
regated human serum albumin) particulate for perfusion
tudies,34,35 68Ga-NOTA-MSA (mannosylated human serum
lbumin) for immune system imaging,36 and 68Ga-BAPEN
Tris(4,6-dimethoxysalicylaldimine)-N,N′-bis(3-aminopropyl)-
,N′-ethylenediamine) myocardial uptake as substitute
or MIBI.37 All these compounds proﬁt from similar afﬁn-
ty of gallium and technetium to some vectors and onlyslightly differentiate biodistribution and pharmacokinetics
(Table 2).
The second trend, taking the generator advantages of inde-
pendence from the cyclotron, much cheaper operation and
production, resulted in the synthesis of 68Ga labeled radio-
pharmaceuticals as an alternative or support to ﬂuorine-18
and carbon-11 compounds. Routine ﬂuorine-18 production
runs are bulk and it is hard to scale them for single patient.
Therefore, ﬂexibility of gallium-68 generators opens the
S18  reports of practical oncology and radiotherapy 1 9 ( 2 0 1 4 ) S13–S21
Table 3 – 68Ga analogs to commonly used 18F and 11C PET tracers.
Diagnostics 18F/11C 68Ga
Angiogenesis 18F-galacto-RGD [68Ga]DOTA-RGD, 68Ga-VEGF
General cancer imaging 18FDG 68Ga-CXCR4 biomarker, 68Ga-uPAR biomarker,
68Ga-SCN-NOTA-BZA
Hypoxia 18F-nitroimidazloes (FAZA, FMISO, FETNIM) 68Ga-DOTA-imidazoles
Proliferation 18FLT 68Ga-DO3A-thymidine
Glioma 18FET, 11C-methionine 68Ga-glutamine, 68Ga-DO3A-alanine,
68Ga-DO2A-tyrosine,
Prostate cancer 18FDG, 11C-acetate, 18F-choline, 11C-choline 68Ga-DOTA-PSMA
Abbreviations:  RGD, arginylglycylaspartic acid; FAZA, [18F]-1--d-(2-deoxy-2-ﬂuoroarabinofuranosyl)-2-nitroimidazole; FMISO, [18F]-
ﬂuoromisonidazole; FETNIM, [18F]-ﬂuoroerythronitroimidazole; FLT, [18F]-ﬂuorothymidine; FET, [18F]-ﬂuoroethyl-l-tyrosine; VEGF, vascular
mideendothelial growth factor; CXCR4, chemokine receptor; BZA, benza
plasminogen activator.
possibility to produce short series or even single doses. While
it is difﬁcult today to imagine the replacement of 18FDG or
leading carbon-11 radiopharmaceuticals in routine clinical
diagnostics, the use of gallium-68 equivalents in targeted diag-
nostics seems to be rapidly developing (Table 3).
4.2.1.  Angiogenesis
Receptors playing a key role in angiogenesis are impor-
tant targets for several experimental drugs. The expression
of the v3 integrin has been detected on blood ves-
sels with the intensive angiogenesis and indicates tumors
with high metastatic potential. One of the most intensely
evaluated compounds so far is [18F]Galacto-RGD38 which
speciﬁcally binds to the v3 integrin and shows very
good pharmacokinetics. Comparable results were received
for [68Ga]DOTA-RGD39 or other RGD peptides linked with
modiﬁed bifunctional ligands: [68Ga]NS3-RGD, [68Ga] Oxo-
DO3A-RGD,40 or four nitrogen atoms open chain H2dedpa.41
Effective diagnosis of angiogenesis was reported as well with
the VEGF (vascular endothelial growth factor) receptors. The
tracer contained single chain VEGF (scVEGF), linked with the
polyethylene glycol (PEG) bridge to NOTA, which was suitable
for labeling with gallium-68 at ambient temperature. Gallium-
68 labeled scVEGFPEG-NOTA was injected intravenously into
HT-29 (human colon adenocarcinoma) tumor-bearing mice,
and clearly visualized tumor structure.42 Labeling procedure
was proposed as a kit-formulated radiopharmaceutical for the
targeted imaging of tumor angiogenesis.
4.2.2.  General  oncology  imaging
Mapping of the chemokine receptor CXCR4 in tumors is
used for rating tumor aggressiveness and estimation of the
metastatic seeding probability in breast, prostate and lung
cancer. Speciﬁc tracer for the imaging of CXCR4, gallium-
68 labeled DOTA-4-FBn-TN14003 (ﬂuorinated 14-aminoacids
peptide) was synthesized as a potential PET tracer for this
purpose.43
Similar studies were performed with the urokinase-
type plasminogen activator receptor (uPAR) which is
a well-established biomarker for tumor aggressiveness
and metastatic potential. The synthetic peptide (Asp-
cyclohexylalanine-Phe-d-Ser-d-Arg-Tyr-Leu-Trp-Ser (AE105))
has been identiﬁed to have a high afﬁnity for human uPAR. The
use of 68Ga-DOTA-AE105-NH2 and 68Ga-NODAGA-AE105-NH2; PSMA, prostate speciﬁc membrane antigen; UPAR, urokinase-type
as the ﬁrst gallium-68 labeled uPAR radiotracers for PET imag-
ing were reported, where NODAGA is a favored tracer providing
highest tumor-to-background ratio.44 These new tracers con-
stitute an interesting alternative to the 64Cu-labeled version
(64Cu-DOTA-AE105 and 64Cu-DOTA-AE105-NH2) for detecting
uPAR expression in tumor tissue.45
Radiolabeled benzamides (BZA) have been reported to be
the attractive agents for targeting malignant melanoma as
they bind melanin and display high accumulation in the
melanoma cells. The 68Ga-labeled benzamide via NOTA was
presented as a potential PET agent for malignant melanoma.
Biodistribution and micro-PET studies of 68Ga-SCN-NOTA-
BZA in B16F10-bearing mice showed selective uptake into the
tumor. The radiotracer was effectively cleared via renal excre-
tion without further metabolism.46
4.2.3.  Hypoxia  imaging
Wide range of ﬂuorine-18 nitroimidazloes have been devel-
oped such as FETNIM ([18F]-ﬂuoroerythronitroimidazole),
FAZA ([18F]-1--d-(2-deoxy-2-ﬂuoroarabinofuranosyl)-
2-nitroimidazole), FETA ([18F]-ﬂuoroetanidazole) and
especially [18F]FMISO, still considered as a gold standard
for hypoxia imaging.47 Copper-64 ATSM (diacetyl-bis(N4-
methylthiosemicarbazone) was indicated as an alternative,
but suffers from less favorable dosimetry, associated with
emission of − (38.5%), and solid target cyclotrone pro-
duction (64Ni(p,n)64Cu) which limits availability. Several
68Ga-complexes with nitroimidazoles were proposed for
hypoxic tumor imaging: DOTA-derivative with one or two
metronidazole moieties,48 imidazole coupled to DOTA by
conjugating via an amide or thiourea bond.49
The results obtained were comparable with reference
images obtained with [18F]FMISO and [18F]FAZA, but the usage
of methylated 5-nitroimidazole improved performance of
68Ga-DOTA-nitroimidazoles in hypoxia imaging.50
4.2.4.  Proliferation
Radiolabeled thymidine analogs speciﬁcally addressing DNA
synthesis have signiﬁcant potential for imaging of tissue pro-
liferation in vivo. [18F]-ﬂuoro-3′-deoxy-3′-l-ﬂuorothymidine
([18F]FLT) has been developed and well-established as a pro-
liferation tracer.
Thus, thymidine analogs substituted by BFC with gallium-
68, were proposed as alternative to [18F]FLT. DO3A macrocycle
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n N-3 position was attached to thymidine and then labeled
ith gallium-68.51
Amino acids labeled with carbon-11 or ﬂuorine-18 play
n important role in clinical diagnostics and understanding
he basic processes in biochemistry and physiology.52–54 They
re involved in the synthesis of peptides and proteins, thus
umor cells concentrate labeled amino acids at a high rate,
hile the uptake in normal cerebral tissue is relatively low.
1C-methionine (MET) and 18F-ﬂuoroethyl-l-tyrosine (FET) are
outinely applied for gross tumor volume delineation in brain
liomas and for the differentiation between treatment-related
hanges and residual/recurrent tumor.
Radiolabeled with gallium-68 glutamine was used for trac-
ng glutamine for imaging and for determination of protein
ynthesis rates in tumors. Glutamine was conjugated to DOTA
nd labeled with gallium-68 by mixing the Ga3+ species with
he conjugate in ethanol and reacting at 65 ◦C.55,56
Alanine derivatives of DO2A and DO3A were synthesized
nd labeled with gallium-68. Cell uptake assays were carried
ut in Hep3B (human hepatoma) and U87MG (human glioma)
ell lines at 37 ◦C. Positron emission tomography (PET) imaging
tudies were performed using balb/c mice xenografted with
T-26 (mouse colon cancer).
68Ga-DO3A-homoalanine showed the highest uptake value
atio, followed by 68Ga-DO2A-alanine, 68Ga-DO3A-alanine and
8Ga-DO2A-homoalanine, but all derivatives were found to
ave high tumor cell uptakes, high tumor/nontumor ratio
nd low nonspeciﬁc uptake in normal organs, except for the
idneys.57
The novel tyrosine chelate (68Ga-DO2A-(OBu-l-tyr)2)
68Ga-1,4,7,10-tetraazacyclododecane-1,7-diacetic acid-4,10-
i-(O-butyl)-l-tyrosine) was proposed as an approach which
ses the biological amino acid transporter targeting properties
f l-tyrosine.
In vitro studies utilizing the F98-glioblastoma cell line
evealed speciﬁc uptake of [68Ga]Ga-DO2A-(OBu-l-tyr)2 that
as comparable to that of the reference [18F]ﬂuoroethyl-
-tyrosine (FET). These promising results indicate a high
otential of tyrosine analogs labeled with GaDOTA for
olecular imaging of tumor-driven amino acid uptake by
ET.58
.2.5.  Prostate  cancer
maging of prostate cancer was dominated by 3 tracers:
8FFDG, acetate and choline, both labeled with ﬂuorine-18 or
arbon-11.59 The prostate speciﬁc membrane antigen (PSMA)
s a unique membrane bound glycoprotein, which is over-
xpressed in prostate cancer and is well-established in the
iagnosis as highly speciﬁc prostate cancer cell-surface pro-
ein. Recently, theranostics concept had been applied to label
SMA-ligands with gallium-68 and lutetium-177.60 Successful
ynthesis of 68Ga-DOTA-PSMA61 and 68Ga(HBED-CC)-PSMA62
as followed by promising results of clinical trials, where
t least one lesion suspicious for cancer was indicated with
00% detection ratio at PSA >2.2 ng/ml. Lesions suspicious
or prostate cancer were presented with excellent contrast as
arly as 1 h post injection, with high detection rates even at
ow PSA levels.63therapy 1 9 ( 2 0 1 4 ) S13–S21 S19
5.  Availability
The effective synthesis of DOTA-TOC and DOTA-TATE were
presented64 and numerous strategies of automated65,66 or
semi-automated67 puriﬁcation and synthesis were proposed.
One of the recent developments inﬂuenced radiopharmaceu-
ticals sciences with a new term “autoclabeling”,68 describing
convenient procedure for gallium-68-labeling by combining
the labeling reaction and the steam sterilization into one sin-
gle step to get the ﬁnal, sterile ready-to-use product. Increase
in clinical and radioprotection demands have boosted for
extensive automation of the production process and resulted
in a number of commercial synthetic modules, but regulatory
restrictions, both requesting GMP-compliant generator and
GMP  regulations for labeling as for the standard drugs, has
retarded the implementation in clinical practice. Both these
obstacles have been overcome and at least one pharmaceu-
tical 68Ge/68Ga generator was ofﬁcially approved for the use
in clinical studies and some modules were registered as GMP-
compliant.69 Additional positive impact could be caused by
the debate on adopting GMP-regulations for microdoses to
PET-radiopharmaceuticals production speciﬁcity,70 intending
to maintain the required quality aspects but not to hamper
innovation and dynamic development of gallium-68 radio-
pharmaceuticals in clinical trials.
6.  Conclusions
Construction of the 68Ge/68Ga generator increased the appli-
cations of radiopharmaceuticals labeled with this isotope in
medicine. The availability of the commercial, pharmaceuti-
cal grade 68Ga/68Ge generator for routine applications and a
favorable chemistry using DOTA, NOTA-derived bifunctional
chelators have opened a brilliant future for the application
of gallium-68 in all ﬁelds of PET imaging. Wide range of the
PET radiopharmaceuticals based on gallium-68 labeling can be
an alternative or complement to the already well-established
radiopharmaceuticals based on ﬂuorine-18 or carbon-11.
Nowadays, a complete replacement of these radioisotopes
is hard to imagine, but the extension of diagnostic procedures
by on-request, short series synthesis of targeted radiophar-
maceuticals labeled with gallium-68, seems to be a very
reasonable option in the nearest future.
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